These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 19886587)

  • 21. First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia/reperfusion model.
    Kloner RA; Dow JS; Bhandari A
    J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):192-6. PubMed ID: 21193683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits.
    Wang WQ; Robertson C; Dhalla AK; Belardinelli L
    J Pharmacol Exp Ther; 2008 Jun; 325(3):875-81. PubMed ID: 18322148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The late Na+ current (INa) inhibitor ranolazine attenuates effects of palmitoyl-L-carnitine to increase late INa and cause ventricular diastolic dysfunction.
    Wu Y; Song Y; Belardinelli L; Shryock JC
    J Pharmacol Exp Ther; 2009 Aug; 330(2):550-7. PubMed ID: 19403851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Ranolazine--new treatment of chronic stable angina pectoris].
    Ahlehoff O; Hansen PR
    Ugeskr Laeger; 2009 Dec; 171(50):3705-7. PubMed ID: 20003868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A focus on antiarrhythmic properties of ranolazine.
    Vizzardi E; D'Aloia A; Quinzani F; Bonadei I; Rovetta R; Bontempi L; Curnis A; Dei Cas L
    J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):353-6. PubMed ID: 22492919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of ranolazine on ventricular vulnerability and defibrillation threshold in the intact porcine heart.
    Kumar K; Nearing BD; Bartoli CR; Kwaku KF; Belardinelli L; Verrier RL
    J Cardiovasc Electrophysiol; 2008 Oct; 19(10):1073-9. PubMed ID: 18479333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ranolazine: an antianginal drug with antiarrhythmic properties.
    Tamargo J; Caballero R; Delpón E
    Expert Rev Cardiovasc Ther; 2011 Jul; 9(7):815-27. PubMed ID: 21809962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ranolazine improves diastolic function in spontaneously hypertensive rats.
    Williams S; Pourrier M; McAfee D; Lin S; Fedida D
    Am J Physiol Heart Circ Physiol; 2014 Mar; 306(6):H867-81. PubMed ID: 24464752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ranolazine reduces remodeling of the right ventricle and provoked arrhythmias in rats with pulmonary hypertension.
    Liles JT; Hoyer K; Oliver J; Chi L; Dhalla AK; Belardinelli L
    J Pharmacol Exp Ther; 2015 Jun; 353(3):480-9. PubMed ID: 25770134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ranolazine: a novel agent that improves dysfunctional sodium channels.
    Pham DQ; Mehta M
    Int J Clin Pract; 2007 May; 61(5):864-72. PubMed ID: 17493093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The electrophysiological properties of ranolazine: a metabolic anti-ischemic drug or an energy-efficient antiarrhythmic agent?
    Cingolani E; Lepor NE; Singh BN
    Rev Cardiovasc Med; 2011; 12(3):136-42. PubMed ID: 22080924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs.
    Minotti G
    J Pharmacol Exp Ther; 2013 Sep; 346(3):343-9. PubMed ID: 23818683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ranolazine is effective for acute or chronic ischemic dysfunction with heart failure.
    Nanda S; Martinez MW; Dey T
    J Am Coll Cardiol; 2010 Aug; 56(10):822; author reply 822. PubMed ID: 20797499
    [No Abstract]   [Full Text] [Related]  

  • 34. Ranolazine in heart failure with preserved left ventricular ejection fraction and microvascular dysfunction: case report and literature review.
    D'Elia E; Fiocca L; Ferrero P; Iacovoni A; Baio P; Medolago G; Duino V; Gori M; Gavazzi A; Senni M
    J Clin Pharmacol; 2013 Jun; 53(6):665-9. PubMed ID: 23585217
    [No Abstract]   [Full Text] [Related]  

  • 35. Improvement in left ventricular systolic and diastolic performance during ranolazine treatment in patients with stable angina.
    Figueredo VM; Pressman GS; Romero-Corral A; Murdock E; Holderbach P; Morris DL
    J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):168-72. PubMed ID: 20924097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ranolazine: new drug. Stable angina: not worth the risk.
    Prescrire Int; 2009 Aug; 18(102):148-7. PubMed ID: 19743543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New treatment options for late Na current, arrhythmias, and diastolic dysfunction.
    Maier LS
    Curr Heart Fail Rep; 2012 Sep; 9(3):183-91. PubMed ID: 22767404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ranolazine--a nicely timed new medical therapy for stable angina.
    Jackson G
    Int J Clin Pract; 2007 Jul; 61(7):1063. PubMed ID: 17577287
    [No Abstract]   [Full Text] [Related]  

  • 39. Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart.
    Kumar K; Nearing BD; Carvas M; Nascimento BC; Acar M; Belardinelli L; Verrier RL
    J Cardiovasc Electrophysiol; 2009 Jul; 20(7):796-802. PubMed ID: 19298570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction.
    Tocchetti CG; Carpi A; Coppola C; Quintavalle C; Rea D; Campesan M; Arcari A; Piscopo G; Cipresso C; Monti MG; De Lorenzo C; Arra C; Condorelli G; Di Lisa F; Maurea N
    Eur J Heart Fail; 2014 Apr; 16(4):358-66. PubMed ID: 24464789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.